| FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome | Oncologist | 2018 | 464 |
| Tumour-targeting bacteria engineered to fight cancer | Nature Reviews Cancer | 2018 | 196 |
| A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review | JAMA Oncology | 2018 | 139 |
| FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia | Clinical Cancer Research | 2018 | 106 |
| Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents | Liver International | 2018 | 105 |
| Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer | Oncotarget | 2018 | 92 |
| FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia | Oncologist | 2018 | 88 |
| Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis | Lancet Oncology, The | 2018 | 82 |
| Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada | Lancet Oncology, The | 2018 | 79 |
| Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer | Journal of Thoracic Oncology | 2018 | 73 |
| Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies | Lancet Haematology,the | 2018 | 62 |
| Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study | Health Affairs | 2018 | 53 |
| Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop | Value in Health | 2018 | 47 |
| Metastasis-free Survival - A New End Point in Prostate Cancer Trials | New England Journal of Medicine | 2018 | 47 |
| Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations | Neurology | 2018 | 42 |
| The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology | Neuro-Oncology | 2018 | 38 |
| Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections | Clinical Cancer Research | 2018 | 34 |
| FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia | Oncologist | 2018 | 28 |
| FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis | Oncologist | 2018 | 20 |
| Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology | Clinical and Translational Science | 2018 | 19 |
| FDA's Approval of the First Biosimilar to Bevacizumab | Clinical Cancer Research | 2018 | 18 |
| The FDA Oncology Center of Excellence and precision medicine | Experimental Biology and Medicine | 2018 | 18 |
| Treatment of Nonmetastatic Unilateral Retinoblastoma in Children | JAMA Ophthalmology | 2018 | 17 |
| Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System | Leukemia and Lymphoma | 2018 | 16 |
| Complexity of Delivering Precision Medicine: Opportunities and Challenges | American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting | 2018 | 11 |
